BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 22753758)

  • 21. Standard treatment and experimental targeted drug therapy for recurrent glioblastoma multiforme.
    Chang SM; Butowski NA; Sneed PK; Garner IV
    Neurosurg Focus; 2006 Apr; 20(4):E4. PubMed ID: 16709035
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular advances of brain tumors in radiation oncology.
    Noda SE; El-Jawahri A; Patel D; Lautenschlaeger T; Siedow M; Chakravarti A
    Semin Radiat Oncol; 2009 Jul; 19(3):171-8. PubMed ID: 19464632
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel approaches and mechanisms of immunotherapy for glioblastoma.
    Hegde M; Bielamowicz KJ; Ahmed N
    Discov Med; 2014 Mar; 17(93):145-54. PubMed ID: 24641957
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting cancer stem cells for treatment of glioblastoma multiforme.
    Cho DY; Lin SZ; Yang WK; Lee HC; Hsu DM; Lin HL; Chen CC; Liu CL; Lee WY; Ho LH
    Cell Transplant; 2013; 22(4):731-9. PubMed ID: 23594862
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Delivery systems and molecular targets of mechanism-based therapies for GBM.
    Phuphanich S; Brat DJ; Olson JJ
    Expert Rev Neurother; 2004 Jul; 4(4):649-63. PubMed ID: 15853584
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antiangiogenic therapies in glioblastoma multiforme.
    McNamara MG; Mason WP
    Expert Rev Anticancer Ther; 2012 May; 12(5):643-54. PubMed ID: 22594899
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging.
    Drabycz S; Roldán G; de Robles P; Adler D; McIntyre JB; Magliocco AM; Cairncross JG; Mitchell JR
    Neuroimage; 2010 Jan; 49(2):1398-405. PubMed ID: 19796694
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients.
    Felsberg J; Rapp M; Loeser S; Fimmers R; Stummer W; Goeppert M; Steiger HJ; Friedensdorf B; Reifenberger G; Sabel MC
    Clin Cancer Res; 2009 Nov; 15(21):6683-93. PubMed ID: 19861461
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [What's next in glioblastoma treatment: Tumor-targeted or immune-targeted therapies?].
    Schernberg A; Marabelle A; Massard C; Armand JP; Dumont S; Deutsch E; Dhermain F
    Bull Cancer; 2016 May; 103(5):484-98. PubMed ID: 27032303
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biomarkers and therapeutic advances in glioblastoma multiforme.
    Sasmita AO; Wong YP; Ling APK
    Asia Pac J Clin Oncol; 2018 Feb; 14(1):40-51. PubMed ID: 28840962
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Principles in the Management of Glioblastoma.
    Roda D; Veiga P; Melo JB; Carreira IM; Ribeiro IP
    Genes (Basel); 2024 Apr; 15(4):. PubMed ID: 38674436
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Chemotherapy and targeted treatments in glioblastomas].
    Chinot O; Soulier P; Frenay M
    Neurochirurgie; 2010 Dec; 56(6):491-8. PubMed ID: 21035151
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular pathways and potential therapeutic targets in glioblastoma multiforme.
    Wardak Z; Choe KS
    Expert Rev Anticancer Ther; 2013 Nov; 13(11):1307-18. PubMed ID: 24168050
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Different T-cell subsets in glioblastoma multiforme and targeted immunotherapy.
    Wang H; Zhou H; Xu J; Lu Y; Ji X; Yao Y; Chao H; Zhang J; Zhang X; Yao S; Wu Y; Wan J
    Cancer Lett; 2021 Jan; 496():134-143. PubMed ID: 33022290
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glioblastoma, a brief review of history, molecular genetics, animal models and novel therapeutic strategies.
    Agnihotri S; Burrell KE; Wolf A; Jalali S; Hawkins C; Rutka JT; Zadeh G
    Arch Immunol Ther Exp (Warsz); 2013 Feb; 61(1):25-41. PubMed ID: 23224339
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glioblastoma multiforme: Pathogenesis and treatment.
    Alifieris C; Trafalis DT
    Pharmacol Ther; 2015 Aug; 152():63-82. PubMed ID: 25944528
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Breaching barriers in glioblastoma. Part I: Molecular pathways and novel treatment approaches.
    Miranda A; Blanco-Prieto M; Sousa J; Pais A; Vitorino C
    Int J Pharm; 2017 Oct; 531(1):372-388. PubMed ID: 28755993
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human mesenchymal stem cells and their paracrine factors for the treatment of brain tumors.
    Chan JK; Lam PY
    Cancer Gene Ther; 2013 Oct; 20(10):539-43. PubMed ID: 24052128
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Standards of care and novel approaches in the management of glioblastoma multiforme.
    Hottinger AF; Stupp R; Homicsko K
    Chin J Cancer; 2014 Jan; 33(1):32-9. PubMed ID: 24384238
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Disentangling the therapeutic tactics in GBM: From bench to bedside and beyond.
    Daisy Precilla S; Kuduvalli SS; Thirugnanasambandhar Sivasubramanian A
    Cell Biol Int; 2021 Jan; 45(1):18-53. PubMed ID: 33049091
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.